Lipegfilgrastim
| Clinical data | |
|---|---|
| Trade names | Lonquex |
| Other names | XM-22 |
| AHFS/Drugs.com | UK Drug Information |
| Routes of administration | Subcutaneous injection |
| Drug class | Immunostimulants, colony-stimulating factors[1] |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Saturable proteolytic enzymes (not cytochrome P450 system mediated)[4] |
| Elimination half-life | 32–62 hours[4] |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C866H1372N226O258S9 + PEG |
| Molar mass | 39000 g·mol−1 |
Lipegfilgrastim, sold under the brand name Lonquex, is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults.[1] It is given by injection under the skin in the abdomen, upper arm or thigh.[1]
The most common side effects include nausea as well as bone and muscle pain.[1]
Lipegfilgrastim is similar to granulocyte colony stimulating factor (G‑CSF), a naturally occurring protein in the body that stimulates the production of white blood cells including neutrophils in the bone marrow.[1] Lipegfilgrastim acts in the same way as G‑CSF, increasing the production of neutrophils and thereby helping to reduce the duration of neutropenia and the occurrence of febrile neutropenia (a sign of infection) in people receiving chemotherapy.[1]
Lipegfilgrastim is a filgrastim biosimilar.[1] In lipegfilgrastim, the filgrastim has been 'pegylated' (attached to polyethylene glycol).[1] This slows down the medicine's removal from the body and allows the medicine to be given less often.[1]
Lipegfilgrastim was authorized for medical use in the European Union in July 2013.[1]
Medical uses
[edit]Lipegfilgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).[1]
References
[edit]- ^ a b c d e f g h i j k "Lonquex EPAR". European Medicines Agency. 17 September 2018. Retrieved 13 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Lonquex - Summary of Product Characteristics (SmPC)". (emc). 3 September 2019. Retrieved 12 July 2020.
- ^ a b Hoggatt J, Tate TA, Pelus LM (2015). "Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia". International Journal of Nanomedicine. 10: 2647–2652. doi:10.2147/IJN.S55796. PMC 4388090. PMID 25878498.
Further reading
[edit]- Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, et al. (September 2018). "Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events". Journal of Oncology Pharmacy Practice. 24 (6): 412–423. doi:10.1177/1078155217714859. PMC 6094503. PMID 28614980.
- Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P (2016). "Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients". Biologics: Targets and Therapy. 10: 1–8. doi:10.2147/BTT.S58597. PMC 4730998. PMID 26858523.
- Zou L, Buchner A, Roberge M, Liu PM (2016). "Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy". Journal of Immunology Research. 2016: 9248061. doi:10.1155/2016/9248061. PMC 4935921. PMID 27419145.
